|Time Commitment:||3 Hrs 0 min over 56 days|
|Credits Available:||2.75 AMA PRA Category 1 Credit(s)™|
Pulmonary Arterial Hypertension (PAH) is a progressive disease and is associated with poor clinical outcomes. Data from the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) has shown that the diagnosis of PAH is often missed or delayed with the average length of time from symptom onset to diagnosis estimated to range from 1 to 3 years.
This initiative provides an experience that goes beyond the presentation of information, to one that provides an opportunity to discuss priorities with knowledgeable experts and peers, share experiences, and formulate actionable plans to improve the quality of care provided to your patients with PAH.
This first module is a Baseline Self Assessment to establish your current familiarity in PAH
This program discusses the associations between early identification, treatment intervention, and outcomes for individuals with pulmonary arterial hypertension.
This program will discuss the diagnostic testing and evaluation of pulmonary arterial hypertension.
This program will discuss the therapeutic choices for the management of pulmonary arterial hypertension.
Assess your familiarity with PAH after completing the Self Study modules.
Please join me for a brief kick-off where you'll have a chance to greet other group members and discuss our collective goals and priorities for the next few weeks. I’m really looking forward to seeing you.
This live discussion will offer an interactive approach to providing optimal care to patients with pulmonary arterial hypertension (PAH). Topics discussed will include early identification of PAH, diagnostic testing for PAH, and therapeutic choices for PAH.
This live conference will focus on reviewing the patient case and group tasks and how the findings can apply to caring for current or future patients with pulmonary arterial hypertension (PAH).
This group task will focus on addressing the diagnosis, assessment and therapeutic options for pulmonary arterial hypertension.